Extended Treatment

After talking in person with 2 FNHL patients I thought it may be helpful to some people considering Single Agent Rituxan to consider the following when developing a treatment plan with their Doctor: Patients with relapsed FNHL who opted for Rituxan monotherapy and were treated with an initial eight weeks of Rituxan survived approximately two-times longer than patients treated for four weeks (23 months versus 13 months). This appears to be true for patients opting for initial Rituxan monotherapy too. Their remissions are generally longer with the 8-week vs 4-week regimen.I think the potential benefit of eight weeks vs four weeks, especially when combined with 24 bi-monthly maintenance doses is worth considering. If it doubles remission time then it may well be more cost effective too. It is also the least side effects of any other treatment. This would be true for patients with no major organ tumors. Just my thoughts. It was very effective in my case (FNHL Stage IV grade 1). But of course I am not a doctor And every case is slightly different though treatment seems to be remarkably similar across the board. It won't hurt to ask about it. Hope this helps someone out there avoid the ravages of traditional chemo.
Comments
Discussion Boards
- 119.2K All Discussion Boards
- 5 CSN Information
- 5 Welcome to CSN
- 119.2K Cancer specific
- 2.7K Anal Cancer
- 424 Bladder Cancer
- 297 Bone Cancers
- 1.6K Brain Cancer
- 28.1K Breast Cancer
- 376 Childhood Cancers
- 27.6K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.6K Head and Neck Cancer
- 6.2K Kidney Cancer
- 642 Leukemia
- 765 Liver Cancer
- 4K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 215 Multiple Myeloma
- 7.1K Ovarian Cancer
- 34 Pancreatic Cancer
- 477 Peritoneal Cancer
- 5K Prostate Cancer
- 1.1K Rare and Other Cancers
- 521 Sarcoma
- 693 Skin Cancer
- 633 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.7K Uterine Cancer
- 6.2K Other Discussion Boards